Alkermes PLC
Chiusa
SettoreSettore sanitario
50.18 4.32
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
47.88
Massimo
51.57
Entrata | -116M -66M |
|---|---|
Vendite | 8.4M 393M |
P/E Media del settore | 51.133 50.958 |
EPS | 0.38 |
Margine di Profitto | -16.92 |
Dipendenti | 2,050 |
EBITDA | -98M -22M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +4.01% upside |
Utili prossimi | 28 lug 2026 |
|---|
Capitalizzazione di Mercato | 2B 7.7B |
|---|---|
Apertura precedente | 45.86 |
Chiusura precedente | 50.18 |
Notizie sul Sentiment di mercato
By Acuity
10%
90%
13 / 342 Classifica in Healthcare
Alkermes PLC Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
